Zacks Investment Research | Oct 09, 2017 09:34PM ET
QIAGEN (NASDAQ:QGEN) has been hogging the limelight on its recent partnership and co-marketing agreement with CENTOGENE AG. The partnership aims at delivering complete Sample to Insight research and clinical testing solutions to end users in the field of rare genetic conditions.
Per the collaboration agreement, QIAGEN will integrate its bioinformatics suite with CENTOGENE’s highly developed CentoMD rare disease variant database with the goal to improvise test understanding. Notably, this integration of CentoMD phenotype/genotype database is expected to considerably enhance QIAGEN Knowledge Base and QIAGEN Clinical Insight (QCI) bioinformatics solution.
Under the co-marketing agreement, QIAGEN will now act as the authorized and exclusive international commercial distribution partner of CentoMD. Also, QIAGEN’s bioinformatics solutions will be licensed by CENTOGENE to support the latter’s extensive rare disease diagnostic testing services.
In a bid to grow its bioinformatics portfolio that offers valuable observations into complex biological data, QIAGEN announced the acquisition of OmicSoft Corporation in January. Through this acquisition, QIAGEN gained access to OmicSoft’s powerful multi-omics data management infrastructure solutions as well as ‘omics’ data bank.
We believe the company’s latest partnership with CENTOGENE is strategic, taking into consideration the huge prospects of bioinformatics globally. According to a Markets and Markets report, the global bioinformatics market is projected to reach a worth of $16.18 billion by 2021, at a CAGR of 21.1%.
We believe increased spending on healthcare by government and private organizations, rising awareness triggering need for nucleic acid and protein sequencing and technological innovations and development on the back of successful partnerships between companies and research institutes will continue to drive growth in the bioinformatics market. Thus, the latest development will help QIAGEN cash in on the bountiful opportunities in the niche market.
Share Price Performance
QIAGEN has been gaining investor confidence on consistently encouraging results. Over the last six months, the company’s share price has outperformed the broader industry . The stock has gained 25.9%, as compared to the broader industry’s 12.3% gain. The company has also surpassed the 8.2% gain of the S&P 500 market over the same time frame.
Zacks Rank & Other Key Picks
QIAGEN currently carries a Zacks Rank #2 (Buy). Other top-ranked stocks in the medical sector are Abbott (NYSE:ABT) , IDEXX Laboratories, Inc. (NASDAQ:IDXX) and Thermo Fisher Scientific Inc. (NYSE:TMO) . Abbott, IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2. You can see Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.